Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
- PMID: 36913501
- DOI: 10.1111/apt.17410
Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
Comment on
-
Systematic review with meta-analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease.Aliment Pharmacol Ther. 2023 Mar;57(6):635-652. doi: 10.1111/apt.17370. Epub 2023 Jan 10. Aliment Pharmacol Ther. 2023. PMID: 36627691
References
REFERENCES
-
- Jayasooriya N, Baillie S, Blackwell J, Bottle A, Petersen I, Creese H, et al. POP-IBD study group. Systematic review with meta-analysis: time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2023;57(6):635-52.
-
- Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108:1744-53.
-
- Pratap Mouli V, Munot K, Ananthakrishnan A, et al. Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease. Aliment Pharmacol Ther. 2017;45(1):27-36.
-
- Gupta A, Pratap Mouli V, Mohta S, Kante B, Kalaivani M, Madhu D, et al. Antitubercular therapy given to differentiate Crohn's disease from intestinal tuberculosis predisposes to stricture formation. J Crohns Colitis. 2020;14(11):1611-8.
Publication types
MeSH terms
LinkOut - more resources
Medical